Evercore Gives Natera (NTRA) Outperform Rating

Natera, Inc. (NASDAQ:NTRA) is one of the 14 Best Aggressive Growth Stocks to Buy According to Analysts. On July 28, Evercore ISI initiated coverage on Natera, Inc. (NASDAQ:NTRA), giving an Outperform rating and setting the price target at $170.

The firm views Natera, Inc. (NASDAQ:NTRA) as a fast-growing diagnostics company. Evercore noted that the company has a “clear first-mover advantage” in Minimal Residual Disease (MRD) testing in oncology. The firm pointed out that Natera, Inc. (NASDAQ:NTRA) has the most clinically validated platform and holds about 80% of the market share.

Evercore Gives Natera (NTRA) Outperform Rating

A laboratory environment with technicians in lab coats conducting molecular testing services.

Evercore also highlighted Natera, Inc.’s (NASDAQ:NTRA) top position in women’s health diagnostics. The company holds the leading market share position in areas like non-invasive prenatal testing (NIPT) and carrier screening services.

Natera, Inc. (NASDAQ:NTRA) is a clinical genetic testing company focused on oncology, women’s health, and organ health.

While we acknowledge the potential of NTRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NTRA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 12 Most Owned Stocks by Hedge Funds So Far in 2025.

Disclosure: None. This article is originally published at Insider Monkey.